Patients receive stimulation in the VIM-nucleus of the thalamus

Patients receive stimulation in the posterior subthalamic area

Action Tremor

Deep Brain Stimulation

Annual eReport to the South-Eastern Norway Health Authority

Oslo University Hospital

A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor

Deep Brain Stimulation in Disabling Action Tremor: A Randomized, Double-blind Study Comparing the Ventral Intermediate Nucleus (VIM) of the Thalamus and the Posterior Subthalamic Area (PSA) / Zona Incerta (The TREMORSTIM Study)

The difference in the change from baseline to the end of each of the two 3-month randomized cross-over periods, in tremor of the contralateral upper limb(s), as evaluated by items 5,6,10-14 and 16-21 in the Fahn-Tolosa-Marin (FTM)-score with VIM- versus PSA-stimulation.

2) The difference in the change from baseline to the end of each of the two 3-month cross-over periods in the items scoring tremor of face/tongue/voice/trunk/lower limb(s), with VIM- versus PSA-stimulation.

Change from baseline to 1-yr with stimulation at the most optimal of 4 electrode contacts of each patient (selected after the second randomization period) of the total FTM-score, tremor of the upper limb(s) (same items as above) and of the items scoring tremor in the face, tongue, voice, trunk, lower limb(s).

Change from baseline to 1-yr of Quality of Life in Essential Tremor (QUEST) scale, and Visual Analogue Scale of Global Disease Burden as assessed by the patient.

Frequency of serious adverse events (surgical complications and stimulation related side-effects), including eventual deterioration on neuropsychological testing , registered during the first year of stimulation.

Inger Marie Skogseid

Consultant, MDPhD

South-Eastern Norway Regional Health Authority

Randomized allocation of half the patients to be stimulated the first 3 months in the VIM-nucleus of the thalamus (VIM) and then 3 months in the posterior subthalamic area (PSA), and for the other half the first 3 months in the PSA and the next 3 months in the VIM

The doctor who assesses the primary outcome measures at 3 and 6 months and the participant are both unaware of which of the two targets is stimulated in the two randomization periods.

Posterior Reversible Encephalopathy Syndrome

Weihai Municipal Hospital

Prognostic Observation of Posterior Reversible Encephalopathy Syndrome

Bo Gao, MD

Associate Chief Physician

Yantai Yuhuangding Hospital

University of Southern California

End Stage Renal Disease

Renal Failure

PAL-40 Active

PAL-40 Placebo

VA Medical Center, Birmingham

Health Economics Resource Center (HERC), Menlo Park

VA Palo Alto Health Care System

VA San Diego Healthcare System, San Diego

VA Eastern Colorado Health Care System, Denver

VA Connecticut Health Care System (West Haven)

VA Medical Center, DC

VA Medical Center, Bay Pines

North Florida/South Georgia Veterans Health System

VA Medical Center, Miami

West Palm Beach VA Medical Center

Edward Hines, Jr. VA Hospital

Richard Roudebush VA Medical Center, Indianapolis

Southeast Veterans Healthcare System, New Orleans

VA Medical Center, Jamaica Plain Campus

VA Ann Arbor Healthcare System

John D. Dingell VA Medical Center, Detroit

VA Medical Center, Minneapolis

G.V. (Sonny) Montgomery VA Medical Center, Jackson

VA Medical Center, Kansas City MO

VA Medical Center, Bronx

VA Western New York Healthcare System at Buffalo

New York Harbor HCS

VA Medical Center, Northport

VA Medical Center, Syracuse

VA Medical Center, Cleveland

VA Medical Center, Dayton

VA Medical Center, Portland

VA Pittsburgh Health Care System

Ralph H Johnson VA Medical Center, Charleston

VA Medical Center, Memphis

VA North Texas Health Care System, Dallas

Michael E. DeBakey VA Medical Center (152)

Hunter Holmes McGuire VA Medical Center

VA Puget Sound Health Care System, Seattle

Zablocki VA Medical Center, Milwaukee

VA Medical Center, San Juan

Homocysteine Study (HOST)

CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)

Jamison, Rex - Study Chair

US Department of Veterans Affairs

Pan American Laboratories

Abbott Diagnostics Division

anticonvulsant

infarto

infarction

anticonvulsant/infarto

A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor

Prognostic Observation of Posterior Reversible Encephalopathy Syndrome

Homocysteine Study (HOST)

O mais completo banco de dados de ervas medicinais apoiado pela ciência